Newsroom

Sorted by: Latest

-

TechCreate Group Ltd. Reports First Half Fiscal Year 2026 Financial and Operational Results

SINGAPORE--(BUSINESS WIRE)--TechCreate Group Ltd. (OTCMKTS: TCGLF) (“TechCreate” or the “Company”), a technology consultancy and advanced software solutions provider specializing in payment solutions, cybersecurity, and digital services, announced its financial and operational results for the six months ended June 30, 2026. Recent Operational Highlights Notified by NYSE American that the Committee for Review will consider the Company’s request for review of the Panel’s decision on October 22, 2...
-

Nectar MCP Brings Consumer and Creator Data to ChatGPT, Claude, Gemini and Copilot

PALO ALTO, Calif.--(BUSINESS WIRE)--Nectar, the agentic growth operating system connecting businesses to consumers, today launched Nectar MCP, which connects a brand's Nectar data to ChatGPT, Claude, Gemini and Copilot. It is built on the Model Context Protocol, the open standard AI assistants use to connect to outside data. AI assistants have become where a lot of marketing work happens. Teams have connected them to their sales numbers and their plans, but the assistants still can't see the cu...
-

Helm.ai unterzeichnet Geschäftsverträge im Wert von 70 Millionen US-Dollar, während seine Plattform für Grundmodelle über den Automobilbereich hinaus in die industrielle Automatisierung und Robotik expandiert

REDWOOD CITY, Kalifornien--(BUSINESS WIRE)--Helm.ai, das auf Fundament-Modellen basierende Softwareunternehmen für physikalische KI, gab heute bekannt, dass es innerhalb eines Zeitraums von 12 Monaten kommerzielle Verträge im Wert von 70 Millionen US-Dollar abgeschlossen hat, die sich auf globale Automobilhersteller, Tier-1-Zulieferer und Unternehmen der industriellen Automatisierung erstrecken. Das Unternehmen ist auf dem Weg zur Erreichung der Gewinnschwelle, da es serienreife Automobilprogra...
-

Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and...
-

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib...
-

トルーナ、創業25年を経てCEO交代計画を発表、創業者フレデリック・シャルル・プティは取締役、シニア・アドバイザー、株主として引き続き関与

ロンドン--(BUSINESS WIRE)--(ビジネスワイヤ) -- 消費者インサイトと市場調査テクノロジーの世界的リーダーであるトルーナは、計画的な経営トップの交代を発表しました。創業者兼最高経営責任者(CEO)のフレデリック・シャルル・プティは、自ら創業した同社を25年間率いてきました。顧客、従業員、パートナーに関わる業務の継続性を確保するために入念に計画された経営継承プロセスの一環として、後任の任命後にCEO職を退く意向です。 交代後も、プティはトルーナの取締役を務め、引き続き同社の主要株主であるとともに、同社の次の成長段階における中核分野について、継続的に戦略的な助言を行う役割を担います。 取締役会は、プティと緊密に協議しながら、体系的な経営継承プロセスを開始しました。顧客、従業員、パートナーに関わる業務の継続性を確保するため、プティとの引き継ぎについて明確に定めた包括的な移行計画が策定されています。取締役会は、次期最高経営責任者の任命を近日中に確定する見込みです。 プティは25年前にトルーナを創業し、世界を代表する多くのブランドや調査会社にサービスを提供するグローバル企業...
-

AHF Champions Girls’ Health, Rights and Futures on International Day of the Girl

LOS ANGELES--(BUSINESS WIRE)--On International Day of the Girl, observed annually on Oct. 11, AIDS Healthcare Foundation (AHF) is calling for greater action to ensure girls everywhere have the health, education, protection, and opportunities they need to thrive and reach their full potential. Despite decades of progress, major barriers continue to limit girls’ opportunities. HIV continues to disproportionately affect girls in many parts of the world. In 2025, girls accounted for more than two-t...
-

Kayne Anderson BDC, Inc. Announces Third Quarter 2026 Earnings Release and Conference Call

CHICAGO--(BUSINESS WIRE)--Kayne Anderson BDC, Inc. (NYSE: KBDC) (“KBDC”), a business development company externally managed by its investment adviser, KA Credit Advisors, LLC, announced today that it will release its financial results for the third quarter ended September 30, 2026, on Thursday, November 5, 2026, after the close of financial markets. KBDC will host a conference call at 12:00 pm ET on Friday, November 6, 2026, to review its financial results. All interested parties are invited to...
-

Susan G. Komen® Announces Band As One Los Angeles, a Concert for the Cure

LOS ANGELES--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, today announced its inaugural Band As One Los Angeles, a Concert for the Cure, a signature fundraising event that brings together a star-studded lineup of musical artists for an unforgettable night of music, stories and solidarity in support of people facing breast cancer. Paula Abdul will headline the event at the Dolby Theatre and be joined by musical friends who share Komen’s commitment to bringing...
-

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress...